Melanotan II (MT-2): Complete Research Guide — Tanning, Libido & Safety 2026

The story of Melanotan begins not with aesthetics but with oncology. Dr. Mac Hadley and colleagues at the University of Arizona reasoned in the 1980s that if people could achieve a protective tan with minimal UV exposure, they could reduce their skin cancer risk by avoiding the prolonged sun that causes DNA damage. The vehicle for this protective tan: a synthetic version of alpha-MSH, the body's own melanin-stimulating hormone.

Natural alpha-MSH is a 13-amino-acid peptide from the pituitary gland that activates MC1R on melanocytes to drive melanin production. It's also rapidly degraded in plasma (half-life of minutes), making it impractical as a drug. The Arizona team developed a cyclic, lactam-bridged analog — [Nle4, D-Phe7]-α-MSH — that was both more potent and more stable. The first version became Melanotan I (now afamelanotide, FDA-approved as Scenesse for erythropoietic protoporphyria). The more potent, shorter analog became Melanotan II.

During Phase I trials at the University of Arizona, male participants reported unexpected spontaneous erections. This incidental finding launched a parallel research program that eventually produced bremelanotide (PT-141), demonstrating that the original cancer-prevention peptide had spawned both a tanning compound and the first female sexual dysfunction drug [1,2,3].

MT-2 is a non-selective melanocortin receptor agonist. The five melanocortin receptors (MC1R-MC5R) govern diverse physiological functions. MT-2 meaningfully activates at least three:

MT-2's tanning mechanism differs fundamentally from UV-induced tanning, which explains why it produces deeper, more even color with dramatically less sun exposure:

Conventional UV tanning: UV radiation damages keratinocyte DNA. Damaged keratinocytes release alpha-MSH and other signals that activate MC1R on adjacent melanocytes. Melanocytes produce melanin and transfer it to surrounding keratinocytes — the visible tan is actually a DNA damage response, with melanin serving as a photoprotective cap over cellular nuclei.

MT-2 tanning: MT-2 directly activates MC1R on melanocytes, bypassing the UV damage requirement entirely. Melanocytes upregulate melanin synthesis proactively. When UV light is then introduced — even minimal amounts (15-30 minutes) — pre-loaded melanocytes produce a dramatically amplified tanning response versus UV alone.

Key practical implications from the clinical data [7]:

• MT-2 can produce visible tanning with 15-30 minutes of sun versus the hours required without it
• Tanning is more even because MT-2 stimulates melanocytes uniformly, not in the patchy UV damage pattern
• MT-2 preferentially stimulates eumelanin (brown-black pigment) over pheomelanin (red-yellow), producing a darker, more "Mediterranean" tone
• Deposited melanin persists for weeks after MT-2 discontinuation, as melanin-loaded keratinocytes gradually cycle out over 4-12 weeks

MT-2 dosing follows a classic two-phase approach — saturation to build melanin deposition, maintenance to preserve it:

MT-2's broad melanocortin receptor activity produces a diverse but mostly transient side effect profile:

PT-141 (bremelanotide) was derived directly from Melanotan II research. When spontaneous erections were reported in early MT-2 trials, researchers worked to identify the responsible receptor (MC4R) and develop a more selective compound targeting sexual function with less tanning and reduced nausea. Bremelanotide received FDA approval in 2019 as Vyleesi for hypoactive sexual desire disorder in premenopausal women [5].

The practical difference:

• MT-2: Non-selective; strong tanning effect (MC1R) + libido/sexual arousal (MC4R) + appetite suppression (MC3R); higher nausea incidence; no FDA approval
• PT-141: More MC4R-directed (though not fully selective); minimal tanning effect; FDA-approved for female sexual dysfunction; more extensive human safety data for the sexual health application; still causes nausea at higher doses

If your primary goal is tanning, MT-2 is the appropriate compound. If sexual function is the primary goal and tanning is unwanted or the target is female sexual dysfunction, PT-141 is both more appropriate and better characterized from a safety standpoint. For the complete PT-141 guide, see our PT-141 Bremelanotide Research Guide.

MT-2 is supplied as a lyophilized white powder. Reconstitution steps:

1. Use bacteriostatic water (BAC water) — not sterile saline, which lacks the preservative required for multi-use vials. BAC water maintains sterility for 28-30 days after opening.
2. Common reconstitution: 10mg vial + 2 mL BAC water = 5 mg/mL. Each 0.1 mL then contains 0.5 mg MT-2.
3. Inject BAC water slowly into the vial by running it down the glass wall — never spray directly onto the powder.
4. Gently swirl until dissolved — never shake. Shaking denatures peptide bonds and reduces activity.
5. Store reconstituted solution refrigerated (2-8°C); use within 4-6 weeks for best stability.
6. Inject subcutaneously with a 29-31 gauge insulin syringe. Pinch skin at abdomen or thigh, 45-degree angle. Rotate injection sites to prevent lipodystrophy.

Melanotan II is one of the most pharmacologically interesting peptides in research use — a compound whose discovery inadvertently launched both a tanning treatment and an FDA-approved sexual dysfunction drug. Its melanocortin receptor biology illustrates how a single molecular mechanism can govern diverse physiological systems from skin pigmentation to appetite to sexual arousal.

For tanning applications, MT-2 is highly effective. It produces eumelanin-based pigmentation deeper and more evenly than UV alone achieves, with a fraction of the UV exposure — and therefore, potentially, a fraction of the UV-related DNA damage. The saturation-then-maintenance protocol is well-established from both clinical trial data and decades of documented use.

The non-negotiable precautions are mole monitoring and the test-dose titration approach. Anyone with melanoma risk factors should consult a dermatologist before starting. Anyone who uses MT-2 should perform regular self-exams and have any changing lesion evaluated promptly. These are not abstract warnings — they reflect the genuine mechanism of MC1R-driven melanocyte stimulation throughout the skin.

For the complete melanocortin receptor biology, clinical trial history, and peptide pharmacology, see the PeptideWiki Melanotan II Database Page. For the PT-141 sexual health application, see our PT-141 Bremelanotide Complete Guide.